{
  "id": 15617992,
  "title": "Gilead’s pill posts stronger colitis remission rates than Entyvio",
  "url": "https://urgent.news/2026/10/19/gileads-pill-posts-stronger-colitis-remission-rates-than-entyvio",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T15:05:39.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/gileads-pill-posts-stronger-colitis-remission-rates-than-entyvio/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Gilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival products. After ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}